Geron is a biopharmaceutical company that sells RYTELO, a treatment for certain blood cancers. It last closed at $0.87 on Nov 20, down 4.63% on the day. The next earnings report for GERN is expected around Wed, Feb 24, 2027. For the quarter ended Sep 2026, GERN reported EPS of $0.00 on revenue of $60.2M, with revenue up 27.4% from a year ago. Over its last 8 reports the stock moved an average of 11.4% the session after earnings. Over the last 12 months GERN insiders bought $62K of stock on the open market and sold $19K, according to SEC Form 4 filings.
AI Auto Pilots
Is GERN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold GERN.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on GERNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
GERN · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 13% below its 20 day and 30% below its 50 day average. It is 60% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 35), near oversold. The nearest support is the Pivot S1 at $0.85, and the nearest resistance the Pivot at $0.89.
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 8.4%/day
Key levels
$2.0152 week high+131.0%
$1.39200 day average+59.8%
$1.30100 day average+49.4%
$1.1350 day average+29.9%
$1.02Swing high (Nov 17)+17.2%
$0.9820 day average+12.6%
$0.91Pivot R1+4.6%
$0.89Pivot+2.3%
$0.87Last close
$0.85Pivot S1−2.3%
$0.8452 week low−3.4%
$0.84Swing low (Oct 28)−3.4%
Indicators
RSI (14)
35.41
Weak, oversold below 30
Neutral
MACD
-0.06
Below its signal line
Bearish
Stochastic
24.9
Middle of its range
Neutral
ADX (14)
34.4
Trending down
Williams %R
-96.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-146.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−12.0%
Change over 10 sessions
Bearish
ATR (14)
$0.07
Typical daily range, 8.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 19.8%/day
Key levels
$2.0152 week high+131.0%
$1.39200 day average+59.8%
$1.30100 day average+49.4%
$1.1350 day average+29.9%
$1.02Swing high (Nov 17)+17.2%
$0.9820 day average+12.6%
$0.91Pivot R1+4.6%
$0.89Pivot+2.3%
$0.87Last close
$0.85Pivot S1−2.3%
$0.8452 week low−3.4%
$0.84Swing low (Oct 28)−3.4%
Indicators
RSI (14)
32.42
Weak, oversold below 30
Neutral
MACD
-0.12
Below its signal line
Bearish
Stochastic
12.7
Near the bottom of its range
Oversold
ADX (14)
21.2
Weak trend
Williams %R
-96.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-143.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−35.5%
Change over 10 sessions
Bearish
ATR (14)
$0.17
Typical daily range, 19.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for GERN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how GERN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow GERN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for GERNHow many large options trades hit GERN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in GERN in the last 90 days.
From SEC Form 4 filings by GERN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GERN is in one of them and how their past GERN trades turned out.
Geron is a biopharmaceutical company based in Foster City, California, that develops treatments for blood cancers. Its main product is RYTELO, a telomerase inhibitor approved in the United States for adults with myelodysplastic syndrome who need frequent red blood cell transfusions. The company sells RYTELO to patients and health care providers in the U.S. and plans to make it available in select European Union markets through outside partners. It is also testing the drug in myelofibrosis, another blood cancer.